Misplaced Pages

Pseudoephedrine/loratadine: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively
Page 1
Page 2
← Previous editContent deleted Content addedVisualWikitext
Revision as of 18:50, 30 June 2011 editAnypodetos (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers, Rollbackers39,350 editsm →Composition: Copyedit← Previous edit Latest revision as of 07:32, 22 December 2024 edit undoWhywhenwhohow (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers49,175 edits rank 
(46 intermediate revisions by 32 users not shown)
Line 1: Line 1:
{{Short description|Allergy medicine}}
{{Merge to|Loratadine|discuss=Talk:Loratadine#Clarinase|date=June 2011}}
{{Use dmy dates|date=July 2024}}
{{drugbox
{{cs1 config |name-list-style=vanc |display-authors=6}}
⚫ | verifiedrevid = 436685903
{{Drugbox
⚫ | type = combo
⚫ | verifiedrevid = 439439973
⚫ | component1 = Pseudoephedrine
⚫ | type = combo
⚫ | class1 = ]

⚫ | component2 = Loratadine
<!--Combo data-->
⚫ | class2 = ]
⚫ | component1 = Pseudoephedrine
⚫ | CAS_number =
⚫ | class1 = ]
⚫ | ATC_prefix = R01
⚫ | component2 = Loratadine
⚫ | ATC_suffix = BA52
⚫ | class2 = ]
| PubChem =

| DrugBank =
<!--Clinical data-->
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| tradename = Claritin-D, others
| pregnancy_US = B
| Drugs.com = {{Drugs.com|parent|claritin-d}}
⚫ | pregnancy_category=
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
⚫ | pregnancy_category =
⚫ | legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
⚫ | routes_of_administration = ]
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
⚫ | ATC_prefix = R01
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
⚫ | ATC_suffix = BA52
| legal_status = ]

⚫ | routes_of_administration = Oral
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
⚫ | legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = OTC
| legal_US_comment = <ref name="Claritin-D FDA label">{{cite web | title=Claritin-D 12 hour- loratadine and pseudoephedrine sulfate tablet, extended release | website=DailyMed | date=30 November 2023 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7125705-01ff-4418-8c53-9209c2bbb484 | access-date=8 July 2024}}</ref>
| legal_status =

<!--Identifiers-->
⚫ | CAS_number = 156098-07-6

<!--Chemical data-->
}} }}


'''Pseudoephedrine/loratadine''' (trade names '''Claritin-D''', '''Clarinase''', '''Clarinase Repetabs''') is an orally administered drug combination for the treatment of ] and the ]. ], one of the naturally occurring alkaloids of ], is a ] used as a ]. It produces its decongestant effect facilitating ] and shrinkage of congested mucosa in upper respiratory areas. ] is a long acting ] that is less ] than older substances of the type. '''Pseudoephedrine/loratadine''', sold under the brand name '''Claritin-D''' among others, is an orally administered ] used for the treatment of ] (hay fever) and the ].<ref name="Claritin-D FDA label" /> ], one of the naturally occurring alkaloids of ], is a ] used as a ].{{medcn|date=July 2024}} It produces a decongestant effect that is facilitated by the ] in the mucosal capillaries of the upper respiratory areas.{{medcn|date=July 2024}} ] is a long-acting ] (H<sub>1</sub> histamine antagonist) that is less ] than older substances of its type.{{medcn|date=July 2024}}


In 2022, it was the 289th most commonly prescribed medication in the United States, with more than 500,000 prescriptions.<ref>{{cite web | title=The Top 300 of 2022 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=30 August 2024 | archive-date=30 August 2024 | archive-url=https://web.archive.org/web/20240830202410/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}</ref><ref>{{cite web | title = Loratadine; Pseudoephedrine Drug Usage Statistics, United States, 2013 - 2022 | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/LoratadinePseudoephedrine | access-date = 30 August 2024 }}</ref>
==Indications and usage==

Clarinase repetabs tablets are indicated for the relief of symptoms associated with allergic rhinitis and the common cold including nasal congestion, ], ], ] and ].
==Medical uses==
Pseudoephedrine/loratadine are indicated for the relief of symptoms associated with allergic rhinitis and the common cold including nasal congestion, ], ], ], and ].<ref name="Claritin-D FDA label" /><ref>{{cite book|title=Austria-Codex|at=Clarinase 5&nbsp;mg/120&nbsp;mg Retardtabletten| veditors = Haberfeld H |publisher=Österreichischer Apothekerverlag|location=Vienna|year=2009|edition=2009/2010|isbn=978-3-85200-196-8|language=German}}</ref>


==Composition== ==Composition==

===Clarinase Repetabs===
{{unreferenced section|date=July 2024}}
A Clarinase Repetab tablet contains 5&nbsp;mg loratadine in the tablet coating and 120&nbsp;mg pseudoephedrine sulfate equally distributed between the tablet coating and the barrier-coated core. The two active components in the coating are quickly liberated; release of pseudoephedrine in the core is delayed for several hours. A Clarinase Repetab tablet contains 5&nbsp;mg loratadine in the tablet coating and 120&nbsp;mg pseudoephedrine sulfate equally distributed between the tablet coating and the barrier-coated core. The two active components in the coating are quickly liberated; release of pseudoephedrine in the core is delayed for several hours.


Line 35: Line 51:


===Interactions=== ===Interactions===
{{unreferenced section|date=July 2024}}
When sympathomimetics are given to patients receiving ]s (MAO inhibitors), hypertensive reactions, including hypertensive crises may occur. The antihypertensive effects of ], ], ] and ] may be reduced by ]. Beta-adrenergic blocking agents may also interact with sympathomimetics. Increase ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with ]. ] increase the rate of pseudoephedrine absorption, ] decreases it.{{Citation needed|date=June 2011}}
When sympathomimetics are given to patients receiving ]s (MAO inhibitors), hypertensive reactions, including ] may occur.


===Adverse effects=== ===Adverse effects===
{{unreferenced section|date=July 2024}}
During controlled clinical studies with the recommended dosage, the incidence of adverse effects was comparable to that of placebo, with the exception of ] and dry mouth, both of which were commonly reported. During controlled clinical studies with the recommended dosage, the incidence of adverse effects was comparable to that of placebo, with the exception of ] and dry mouth, both of which were commonly reported.


===Contraindications=== ===Contraindications===
{{unreferenced section|date=July 2024}}
Clarinase is contraindicated in patients receiving MAO inhibitor therapy or within 14 days of discontinuing such treatment and in patients with narrow angle ], urinary retention, severe ], severe ] and ]. Pseudoephedrine/loratadine is contraindicated in people receiving ] therapy or within 14 days of discontinuing such treatment and in people with narrow angle ], urinary retention, severe ], severe ] and ].

== Society and culture ==
=== Brand names ===
It is sold under various brand names including Claritin-D, Clarinase, Clarinase Repetabs, Lorinase, Rhinos SR, and Allerclear-D.


==References== ==References==
{{reflist}}
* Drugs.com:
* Israel Ministry of Health:
* {{cite book|title=Austria-Codex|editor=Haberfeld, H|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2009|edition=2009/2010|isbn=3-85200-196-X|language=German}}


{{Nasal preparations}} {{Nasal preparations}}
{{Portal bar | Medicine}}
{{Authority control}}


{{DEFAULTSORT:Pseudoephedrine Loratadine}}
] ]
]
] ]
] ]

]